Cargando…
Loading, please waitCargando…
Loading, please waitConditions
Multiple sclerosis is a chronic autoimmune neurological disease. The foundation of treatment is disease-modifying therapy (DMT) under neurology follow-up. The mesenchymal stem cell therapy we offer is strictly an investigational adjunct coordinated around your neurologist — never a replacement.
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system in which the immune system attacks myelin, the sheath that insulates nerve fibers in the brain, spinal cord and optic nerves. Repeated demyelination disrupts electrical signaling and, over time, leads to axonal loss, scarring and accumulating neurological disability.
MS affects an estimated 2.8 million people worldwide, with a 2-to-3 female-to-male ratio and most diagnoses occurring between 20 and 40 years of age. It is one of the most common non-traumatic causes of neurological disability in young adults. Geographic prevalence varies, with higher rates at latitudes farther from the equator.
MS does not behave the same way in everyone. Relapsing-remitting MS (RRMS) is characterized by discrete attacks followed by partial or complete recovery and accounts for most cases at diagnosis. Secondary progressive MS (SPMS) tends to emerge years after RRMS and involves steadier neurological decline. Primary progressive MS (PPMS) presents with continuous progression from onset without clear relapses. This distinction is clinically decisive: pharmacological and regenerative evidence is not uniform across subtypes.
Diagnosis is established by the McDonald criteria (2017 revision and subsequent updates), combining clinical presentation, brain and spinal cord MRI findings and, when needed, cerebrospinal fluid analysis (oligoclonal bands). Disease-modifying therapies — interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, natalizumab, ocrelizumab, ofatumumab, cladribine and others — have transformed the prognosis of RRMS and are the cornerstone of modern treatment.
At Regeneris Therapy in Cancún, we do not replace that neurological framework. When appropriate, and always in coordination with your treating neurologist, mesenchymal stem cell (MSC) therapy may be considered as an investigational adjunct aimed at immune modulation and neuroprotective support. Every case is evaluated honestly, and we respectfully redirect many patients when an adjunctive therapy is not the right call.
Multiple sclerosis is multifactorial: a complex genetic susceptibility combines with environmental exposures that, at some point, trigger an autoimmune response against central nervous system myelin. There is no single cause.
Genetic predisposition is well documented. The HLA-DRB1*15:01 allele carries the largest known individual risk, and more than 230 genetic variants have been associated with MS susceptibility. A first-degree relative with MS raises the risk 15 to 30 times above the general population, although the absolute risk remains low.
Among the most robust environmental factors are: Epstein-Barr virus infection (a landmark longitudinal study published in Science in 2022 showed that EBV infection multiplies MS risk 32-fold and precedes diagnosis by years), vitamin D deficiency, active and passive smoking, adolescent obesity and living at higher latitudes during childhood. The interaction of these factors with host genetics appears to ignite the disease.
Pathologically, autoreactive T and B cells cross the blood-brain barrier and attack myelin and the oligodendrocytes that produce it. Chronic inflammation leads to demyelination, cumulative axonal injury and, over time, neurodegeneration. Demyelinating lesions ("plaques") are visible on MRI and their location explains much of the clinical variability between patients.
We want to be unambiguous: mesenchymal stem cell (MSC) therapy is not a cure for multiple sclerosis and is not a replacement for disease-modifying therapy. Approved DMTs — interferons, glatiramer, fumarates, S1P modulators, anti-CD20 monoclonal antibodies such as ocrelizumab and ofatumumab, natalizumab, cladribine — are the cornerstone of modern RRMS treatment and have transformed its prognosis. At Regeneris we only consider MSC therapy as an investigational adjunct for patients whose MS is already under neurology follow-up and whose neurologist knows and agrees with the plan.
The distinction between MSC and HSCT (autologous hematopoietic stem cell transplantation) is critical and almost never explained well online. HSCT is a high-intensity hospital-based hematology procedure that uses immunoablative chemotherapy to "erase" the immune system and rebuild it. It has the most robust evidence in highly active RRMS in selected young patients, but it carries serious hospital-grade risks and a procedure-related mortality historically between 0.3 % and 2 %. Regeneris Therapy does NOT perform HSCT. HSCT should only be offered at tertiary hematology centers with intensive care backup and specific transplant experience. Any regenerative clinic offering "HSCT" outside a hospital should raise serious concerns.
MSCs are a different cell population. They do not replace the immune system — they modulate it. They are typically derived from umbilical cord, bone marrow or adipose tissue and administered intravenously. Proposed mechanisms, supported by preclinical and translational research, include peripheral immunomodulation with expansion of regulatory T cells, reduction of pro-inflammatory cytokines (IL-17, IFN-γ, TNF-α), paracrine neurotrophic support (BDNF, NGF, GDNF), stimulation of oligodendrocyte progenitor activity and possible blood-brain barrier stabilization. None of these mechanisms substitutes for what an anti-CD20 antibody or an S1P modulator does: the logic is complementary, not competitive.
The clinical evidence available through 2026 — including the MESEMS consortium and phase I/II trials of allogeneic umbilical-cord MSCs — has shown a reasonable safety profile and early signals of immunomodulation, with efficacy results more modest and heterogeneous than those of HSCT or high-efficacy DMTs. The literature does not support promises of cure, reversal of disability or guaranteed halting of progression. Our protocol at Regeneris uses allogeneic umbilical-cord MSCs processed in COFEPRIS-licensed Mexican laboratories, with documented traceability, cell counts and viability and sterility testing. Applications are intravenous, scheduled in windows that do not interfere with your DMT infusions (for example, ocrelizumab), and always with the knowledge and coordination of your neurologist.
Linked protocols
Intravenous allogeneic MSC protocol as an adjunct to DMTs, never in their place.
Our physicians coordinate every case with your neurologist before any regenerative protocol is offered.
Vitamins, antioxidants and NAD+ protocols to support fatigue and energy alongside your neurology care.
Explore regenerative medicine
See the full landscape of treatments we offer in Cancún and the science behind each one.
The prognosis of MS has changed remarkably over the last two decades. With high-efficacy DMTs started early, many RRMS patients achieve extended periods of NEDA (no evidence of disease activity): no clinical relapses, no new MRI lesions and no disability progression on the EDSS scale. Prognosis depends on clinical subtype, age at onset, degree of imaging activity, response to DMT and modifiable factors such as smoking, vitamin D status and comorbidities.
Progressive forms (SPMS, PPMS) have a more prominent neurodegenerative component and more limited pharmacological options, although useful interventions still exist. Neurological rehabilitation, symptomatic management (spasticity, bladder, fatigue, neuropathic pain), nutrition, adapted exercise and psychological support are essential components of care, regardless of subtype.
We owe patients clarity: MSC therapy does not cure MS. It does not reverse established axonal damage. It does not guarantee halting of progression. It does not replace DMTs or rehabilitation. What current evidence suggests, in carefully selected patients and as part of an integrated plan, is a possible additional immunomodulatory and neuroprotective input alongside conventional care. Honesty about these expectations is part of the standard of care this disease demands.
For some patients, that potential contribution can be meaningful after a frank conversation with their neurologist and a regenerative medicine team. For others, the most responsible recommendation is to optimize the DMT, address lifestyle factors and continue follow-up without adding an investigational therapy. We have made both recommendations to patients and will continue to do so based on what each individual situation actually warrants.
No. Multiple sclerosis, today, has no cure. No treatment — conventional or regenerative — eliminates it completely. What disease-modifying therapies (DMTs) have shown is reduction of relapses, fewer new lesions and slower disability progression. The mesenchymal stem cells (MSC) we offer as an adjunct have documented immunomodulatory and neuroprotective effects but are not curative. Any clinic promising a cure or guaranteed halting of MS with stem cells is overstating what the evidence supports.
Revisado por Dra. Claudia Labastida · 2026-05-18
They are two completely different therapies. HSCT (autologous hematopoietic stem cell transplantation) is a hospital-based hematology procedure that uses immunoablative chemotherapy to erase and rebuild the immune system. It has the best evidence in highly active relapsing-remitting MS in selected young patients, but carries serious risks and procedure-related mortality, and is performed only in tertiary hematology centers. MSCs (mesenchymal stem cells) are a distinct population given intravenously to modulate the immune system, not replace it. They have a better safety profile but also more modest clinical effects. Regeneris offers MSC as an adjunct; we do NOT perform HSCT.
Revisado por Dra. Claudia Labastida · 2026-05-18
No, absolutely not. DMTs are the foundation of your treatment and must continue according to your neurologist's instructions. Any adjustment to your medication is decided by your treating neurologist, not by us. In fact, we do not accept patients who pursue MSC therapy as an excuse to stop their DMT. We coordinate the timing of applications so they do not interfere with your infusions of ocrelizumab, ofatumumab, natalizumab or other agents, and we maintain communication with your neurology team.
Revisado por Dra. Claudia Labastida · 2026-05-18
It depends on the individual profile, but in general the evidence in progressive MS without inflammatory activity is more limited and outcomes are more conservative than in active relapsing-remitting MS. We are especially honest in these cases: if the dominant component is neurodegenerative without significant inflammation, MSC therapy may add little, and other interventions (rehabilitation, symptomatic management, optimization with your neurologist) tend to be the priority. We will tell you clearly after reviewing your history and studies.
Revisado por Dra. Claudia Labastida · 2026-05-18
The safety profile described in the literature for intravenous MSC in MS, in selected patients, is reasonable. Before any application we perform a complete clinical history, imaging review, laboratory work and coordination with your neurologist. We only work with traceable cellular products, processed in COFEPRIS-licensed Mexican laboratories. Adverse effects described are generally mild and transient (brief fatigue, headache, low-grade fever). We do not apply MSC during an active relapse, nor in patients with active infections, severe immunosuppression or active malignancy.
Revisado por Dra. Claudia Labastida · 2026-05-18
Your neurologist remains the lead of your MS care. We do not order or interpret your routine MRIs, disease-activity panels or DMT adjustments — those belong with your neurologist. Our role is strictly adjunctive. Before any protocol we ask for a copy of your recent neurology notes and studies, contact your treating physician when possible, and document every intervention so your neurology team has complete information.
Revisado por Dra. Claudia Labastida · 2026-05-18
Timing varies, and clinical effects in MS are inherently difficult to attribute to a single intervention. When there is a response, subjective changes in fatigue, energy or quality of life tend to appear over weeks to a few months. Changes in biological markers or imaging require longer periods and must be evaluated by your neurologist in the context of your DMT and disease activity. We are honest: not every patient notices changes, and we cannot guarantee specific outcomes.
Revisado por Dra. Claudia Labastida · 2026-05-18
Regenerative medicine and IV therapy applications take place at our clinic in Cancún, where we operate under a COFEPRIS aviso de funcionamiento. The initial evaluation can begin by video consultation — reviewing your clinical history, MRIs and neurology summary — to determine whether it makes sense to continue with an in-person evaluation. If you are traveling from outside Mexico, we help coordinate logistics, lodging and scheduling, and we work to ensure your stay integrates with the follow-up provided by your neurologist back home.
Revisado por Dra. Claudia Labastida · 2026-05-18
An honest medical review of stem cell therapy for MS: the difference between MSC and HSCT, current clinical evidence, ideal candidates, and known limitations.
An evidence-based overview of current research into mesenchymal stem cells and exosomes for autoimmune diseases, including lupus, rheumatoid arthritis, and multiple sclerosis.
Knee osteoarthritis (gonarthrosis, ICD-10 M17) is the progressive wear of the cartilage that covers the femur, tibia and patella. At Regeneris Therapy we combine current clinical evidence and regenerative medicine to reduce pain, improve mobility and, in selected cases, postpone or avoid total knee replacement.
Learn about Knee OsteoarthritisLumbar disc herniation (ICD-10 M51.2) occurs when the nucleus pulposus of an intervertebral disc displaces through the annulus fibrosus and compresses neighboring nerve structures. At Regeneris Therapy we combine an honest evaluation, recent imaging and mesenchymal stem cell therapy as a middle path between failed conservative care and surgery — for patients who meet clear clinical criteria.
Learn about Lumbar Disc HerniationFibromyalgia is real, medical and deserves an honest approach. At Regeneris Therapy we combine regenerative medicine, IV therapy and an integrative protocol to help you recover energy, sleep and quality of life — always alongside your rheumatologist.
Learn about Fibromyalgia in Cancún: Symptoms, Causes and Regenerative OptionsNext step
If you live with multiple sclerosis and want to understand whether mesenchymal stem cell therapy could ever fit as an adjunct to your neurology care, book an honest medical evaluation in Cancún. We coordinate with your treating neurologist and only recommend the adjunct when it is safe and appropriate. If the answer is "not now" or "not for you," we will tell you with the same clarity.